JP2006512891A - 糸状菌における機能性抗体の生産 - Google Patents

糸状菌における機能性抗体の生産 Download PDF

Info

Publication number
JP2006512891A
JP2006512891A JP2003586327A JP2003586327A JP2006512891A JP 2006512891 A JP2006512891 A JP 2006512891A JP 2003586327 A JP2003586327 A JP 2003586327A JP 2003586327 A JP2003586327 A JP 2003586327A JP 2006512891 A JP2006512891 A JP 2006512891A
Authority
JP
Japan
Prior art keywords
nucleic acid
monoclonal antibody
immunoglobulin
fusion
glucoamylase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003586327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006512891A5 (https=
Inventor
パワー、スコット・ディー
ワン、ホアミン
ワード、マイケル
Original Assignee
ジェネンコー・インターナショナル・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29255585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2006512891(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ジェネンコー・インターナショナル・インク filed Critical ジェネンコー・インターナショナル・インク
Publication of JP2006512891A publication Critical patent/JP2006512891A/ja
Publication of JP2006512891A5 publication Critical patent/JP2006512891A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2003586327A 2002-04-18 2003-04-17 糸状菌における機能性抗体の生産 Pending JP2006512891A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37388902P 2002-04-18 2002-04-18
US41153702P 2002-09-18 2002-09-18
US41154002P 2002-09-18 2002-09-18
US45213403P 2003-03-04 2003-03-04
PCT/US2003/012246 WO2003089614A2 (en) 2002-04-18 2003-04-17 Production of functional antibodies in filamentous fungi

Publications (2)

Publication Number Publication Date
JP2006512891A true JP2006512891A (ja) 2006-04-20
JP2006512891A5 JP2006512891A5 (https=) 2006-06-08

Family

ID=29255585

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003586327A Pending JP2006512891A (ja) 2002-04-18 2003-04-17 糸状菌における機能性抗体の生産

Country Status (6)

Country Link
US (2) US20040018573A1 (https=)
EP (1) EP1495055B1 (https=)
JP (1) JP2006512891A (https=)
AU (1) AU2003222664A1 (https=)
DK (1) DK1495055T3 (https=)
WO (1) WO2003089614A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009060804A (ja) * 2007-09-04 2009-03-26 National Research Inst Of Brewing ピヒア属酵母において異種タンパク質を高分泌させる方法
JP2010183885A (ja) * 2009-02-13 2010-08-26 Kobe Univ タンパク質の製造方法およびそれに用いる発現ベクター
KR20200066340A (ko) 2017-10-10 2020-06-09 아지노모토 가부시키가이샤 단백질의 제조 방법
WO2021251383A1 (ja) 2020-06-11 2021-12-16 味の素株式会社 タンパク質の製造法

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1495055T3 (da) * 2002-04-18 2013-11-11 Genencor Int Produktion af funktionelle antistoffer i filamentøse svampe
DK1578774T3 (da) * 2002-09-18 2014-02-03 Danisco Us Inc Oprensning af immunoglobuliner
US7208585B2 (en) * 2002-09-18 2007-04-24 Genencor International, Inc. Protein purification
CA2534055A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
RS50516B (sr) * 2003-11-05 2010-05-07 Ares Trading S.A. Prečišćavanje il-18 vezujućeg proteina
AR047440A1 (es) * 2004-01-21 2006-01-18 Novozymes As Produccion de un anticuerpo monoclonal en un hongo heterocarion o una celula huesped fungal
WO2007045248A1 (en) * 2005-10-17 2007-04-26 Novozymes A/S Use of fungal mutants for expression of antibodies
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
US8198046B2 (en) 2006-07-11 2012-06-12 Danisco Us Inc. KEX2 cleavage regions of recombinant fusion proteins
US20080026376A1 (en) 2006-07-11 2008-01-31 Huaming Wang KEX2 cleavage regions of recombinant fusion proteins
DK2046819T3 (da) 2006-07-21 2015-06-22 Novozymes Inc Fremgangsmåder til forøgelse af secernering af polypeptider med biologisk aktivitet
EP2102240A2 (en) * 2007-01-05 2009-09-23 Novozymes A/S Overexpression of the chaperone bip in a heterokaryon
WO2008115596A2 (en) * 2007-03-21 2008-09-25 Danisco Us, Inc., Genencor Division Over expression of foldases and chaperones improves protein production
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
JP2011507507A (ja) * 2007-12-21 2011-03-10 フジフィルム・マニュファクチュアリング・ヨーロッパ・ベスローテン・フエンノートシャップ マルチマー性前駆体のｉｎｖｉｖｏタンパク質分解的プロセシングによる関心対象のタンパク質の分泌収量の改善
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
NZ603698A (en) 2008-07-08 2014-03-28 Abbvie Inc Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
CN102459330B (zh) * 2009-05-07 2014-11-05 诺维信生物制药丹麦公司 控制抗体的o-联糖基化的方法
DK2427486T3 (en) 2009-05-07 2015-05-26 Novozymes Biopharma Dk As A process for purifying albumin
WO2010141468A1 (en) * 2009-06-01 2010-12-09 Way Jeffrey C Methods and molecules for yield improvement involving metabolic engineering
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PE20140229A1 (es) 2010-08-26 2014-03-27 Abbvie Inc Inmunoglobulinas con dominio variable dual y usos de las mismas
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
DK2800809T3 (en) 2012-01-05 2018-05-22 Glykos Finland Oy PROTEASE-DEFECTED FILAMENTARY FUNGAL CELLS AND PROCEDURES FOR USE THEREOF
KR101505157B1 (ko) 2012-05-08 2015-03-24 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
WO2013174927A1 (en) 2012-05-23 2013-11-28 Novartis International Pharmaceutical Limited Production of fucosylated glycoproteins
KR20180008921A (ko) 2012-11-01 2018-01-24 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
US20140273094A1 (en) * 2013-03-15 2014-09-18 Bristol-Myers Squibb Company Methods of enhancing protein quality and quantity by yeast fed-batch fermentation
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
US10435731B2 (en) 2013-07-10 2019-10-08 Glykos Finland Oy Multiple proteases deficient filamentous fungal cells and methods of use thereof
SG11201700446XA (en) 2014-07-21 2017-02-27 Glykos Finland Oy Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
KR101515535B1 (ko) 2015-01-28 2015-05-06 주식회사 종근당 항―ＥｒｂＢ２ 항체 변이체
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
CN107674900B (zh) * 2017-06-12 2021-05-14 诺利如一（安阳）生物科技有限公司 一种采用串联膜浓缩大豆肽的工艺方法
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
CN113874392B (zh) 2019-03-28 2025-10-21 丹尼斯科美国公司 工程化抗体
WO2021202473A2 (en) 2020-03-30 2021-10-07 Danisco Us Inc Engineered antibodies
CN119630280A (zh) 2022-05-14 2025-03-14 诺维信公司 用于预防、处理、抑制和/或消除植物病原性侵染和感染的组合物和方法
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
EP4574840A1 (en) 2022-08-15 2025-06-25 The University of Tokyo Method for producing immunoglobulin or multimer immunoglobulin using filamentous fungus

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3009104C2 (de) 1980-03-10 1990-10-04 Odenwald-Chemie GmbH, 6901 Schönau Verwendung eines Epoxydharzes zur Herstellung von feuerhemmenden Schichten oder Überzügen und Verfahren zur Herstellung derselben
CA1338400C (en) 1983-08-31 1996-06-18 David H. Gelfand Recombinant fungal cellulases
DE3650202T3 (de) 1985-08-29 2004-06-03 Genencor International, Inc., South San Francisco Expression von heterologen Polypeptiden in filamentösen Pilzen, Verfahren zu deren Herstellung und Vektoren zu deren Herstellung.
US20020061560A1 (en) * 1985-08-29 2002-05-23 Genencor, Inc. DNA sequences, vectors, and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US5679543A (en) * 1985-08-29 1997-10-21 Genencor International, Inc. DNA sequences, vectors and fusion polypeptides to increase secretion of desired polypeptides from filamentous fungi
US5364770A (en) 1985-08-29 1994-11-15 Genencor International Inc. Heterologous polypeptides expressed in aspergillus
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5610034A (en) * 1987-04-29 1997-03-11 Alko Group Ltd. Immunoglobulin production by trichoderma
US5218093A (en) 1989-03-01 1993-06-08 Allelix Biopharmaceuticals, Inc. EGF variants and pharmaceutical use thereof
GB9215540D0 (en) * 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
WO1994025591A1 (en) * 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US5643745A (en) * 1994-02-03 1997-07-01 University Of Hawaii Heterologous dimeric proteins produced in heterokaryons
US5683899A (en) * 1994-02-03 1997-11-04 University Of Hawaii Methods and compositions for combinatorial-based discovery of new multimeric molecules
US6300114B1 (en) * 1994-07-29 2001-10-09 Rohm Enzyme Finland Oy Sequences of xylanase and xylanase expression vectors
EP2295581A3 (en) * 1996-01-19 2011-05-04 Novozymes Biotech, Inc. Morphological mutants of filamentous fungi
US6140113A (en) * 1996-03-28 2000-10-31 The Johns Hopkins University Polynucleotides encoding molecular complexes which modify immune responses
US6265204B1 (en) 1997-01-17 2001-07-24 Genencor International, Inc. DNA sequences, vectors, and fusion polypeptides for secretion of polypeptides in filamentous fungi
GB9703406D0 (en) * 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6232112B1 (en) * 1997-11-24 2001-05-15 Flinders Technologies Pty Ltd Of Flinders University Reagents and methods for diversification of DNA
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
CZ20003099A3 (cs) * 1998-02-25 2002-04-17 Lexigen Pharmaceuticals Corporation Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek
WO2000023579A1 (en) 1998-10-22 2000-04-27 The Regents Of The University Of California Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof
US6767701B1 (en) * 1998-10-26 2004-07-27 Novozymes A/S Methods of constructing and screening a DNA library of interest in filamentous fungal cells
WO2000025574A1 (en) * 1998-10-30 2000-05-11 Thomas Jefferson University Production of biomedical peptides and proteins in plants using plant virus vectors
US7094571B2 (en) * 2000-10-27 2006-08-22 The Board Of Regents Of The University Of Texas System Combinatorial protein library screening by periplasmic expression
US7083945B1 (en) * 2000-10-27 2006-08-01 The Board Of Regents Of The University Of Texas System Isolation of binding proteins with high affinity to ligands
ES2329012T3 (es) * 2000-11-07 2009-11-20 Zymogenetics, Inc. Receptor del factor de necrosis tumoral humano.
EP1340088B1 (en) * 2000-11-17 2007-01-17 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
BRPI0209933B8 (pt) * 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
DK1495055T3 (da) * 2002-04-18 2013-11-11 Genencor Int Produktion af funktionelle antistoffer i filamentøse svampe
US7611866B2 (en) * 2002-07-15 2009-11-03 Board Of Regents, The University Of Texas System Selection of bacterial inner-membrane anchor polypeptides
EP3263596A1 (en) * 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
EP1588166A4 (en) * 2003-01-09 2007-06-27 Macrogenics Inc VECTOR SYSTEM WITH DOUBLE EXPRESSION FOR EXPRESSING ANTIBODIES IN BACTERIAL AND MAMMAL CELLS
US20060024782A1 (en) * 2004-01-21 2006-02-02 Novozymes A/S Production of a monoclonal antibody in a heterokaryon filamentous fungus or in a filamentous fungal host cell
WO2005103074A2 (en) * 2004-03-18 2005-11-03 Board Of Regents, The University Of Texas System Combinatorial protein library screening by periplasmic expression
WO2008067547A2 (en) * 2006-11-30 2008-06-05 Research Development Foundation Improved immunoglobulin libraries
AU2008247819B2 (en) * 2007-05-01 2013-02-14 Research Development Foundation Immunoglobulin Fc libraries

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009060804A (ja) * 2007-09-04 2009-03-26 National Research Inst Of Brewing ピヒア属酵母において異種タンパク質を高分泌させる方法
JP2010183885A (ja) * 2009-02-13 2010-08-26 Kobe Univ タンパク質の製造方法およびそれに用いる発現ベクター
KR20200066340A (ko) 2017-10-10 2020-06-09 아지노모토 가부시키가이샤 단백질의 제조 방법
US11746342B2 (en) 2017-10-10 2023-09-05 Ajinomoto Co., Inc. Method for manufacturing protein
WO2021251383A1 (ja) 2020-06-11 2021-12-16 味の素株式会社 タンパク質の製造法
KR20230023751A (ko) 2020-06-11 2023-02-17 아지노모토 가부시키가이샤 단백질의 제조법
US12492370B2 (en) 2020-06-11 2025-12-09 Ajinomoto Co., Inc. Method for producing protein using a Talaromyces cellulolyticus strain having reduced activity of PEP4

Also Published As

Publication number Publication date
US20040018573A1 (en) 2004-01-29
AU2003222664A8 (en) 2003-11-03
EP1495055B1 (en) 2013-08-14
EP1495055A2 (en) 2005-01-12
EP1495055A4 (en) 2007-08-01
WO2003089614A2 (en) 2003-10-30
DK1495055T3 (da) 2013-11-11
US7977067B2 (en) 2011-07-12
WO2003089614A3 (en) 2004-02-26
AU2003222664A1 (en) 2003-11-03
US20050158825A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
EP1495055B1 (en) Production of functional antibodies in filamentous fungi
JP6840908B1 (ja) エフェクター機能が除去されたＩｇＧ１ Ｆｃ変異体
EP2542575B1 (en) Expression of monoclonal antibodies in tetrahymena
JP6475167B2 (ja) ジスルフィド結合した多価ｍｈｃクラスｉを含む多機能タンパク質
US20180291103A1 (en) Single domain antibody and derivative proteins thereof against programmed death-ligand (pdl1)
US20190169309A1 (en) Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class 1 compromising multi-function proteins
US8518667B2 (en) KEX2 cleavage regions of recombinant fusion proteins
CN110229235A (zh) 利用包含mhc i类的复合物通过循环中的病毒特异性细胞毒性t细胞清除靶细胞
CN113474372A (zh) 一种抗ceacam5的单克隆抗体及其制备方法和用途
JP2007535913A (ja) ヘテロカリオン菌類又は菌類宿主細胞におけるモノクローナル抗体の生成
JP2025500971A (ja) 新規の抗ｔｓｌｐ抗体
JP2008538926A (ja) 切断可能なリンカーを有する一本鎖抗体
JP2021514625A (ja) 抗ｍｕｃ１抗体およびｉｌ−１５を含む融合タンパク質構築物
EP4168454A1 (en) Antibodies and methods for treating claudin-associated diseases
US8198046B2 (en) KEX2 cleavage regions of recombinant fusion proteins
EP3019601B1 (en) Methods for producing sialylated therapeutic proteins
US20250206824A1 (en) GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
US20250154262A1 (en) Fc DOMAIN VARIANTS WITH ENHANCED Fc RECEPTOR BINDING
US20250002593A1 (en) Novel anti-il-36r antibodies
HK40092400A (zh) 用於治疗claudin相关疾病的抗体和方法
Jung Engineering of aglycosylated antibody Fc for effector functions

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090406

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090811